These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 28869890)

  • 1. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
    Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
    J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
    Vyas AK; Sharma BC; Sarin SK; Trehanpati N
    Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies.
    Xiang Y; Chen P; Xia JR; Zhang LP
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: a rare opportunistic illness.
    Landrum ML; Roediger MP; Fieberg AM; Weintrob AC; Okulicz JF; Crum-Cianflone NF; Ganesan A; Lalani T; Macalino GE; Chun HM
    J Med Virol; 2011 Sep; 83(9):1537-43. PubMed ID: 21739443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
    Zhang RF; Liu L; Zheng YF; Shen YZ; Chen J; Gu SM; Wang JR; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hepatitis B markers in Senegalese HIV-1-infected patients.
    Lô G; Sow-Sall A; Diop-Ndiaye H; Mandiouba NC; Thiam M; Diop F; Ndiaye O; Gueye SB; Seck SM; Dioura AA; Mbow M; Gaye-Diallo A; Mboup S; Touré-Kâne C
    J Med Virol; 2016 Mar; 88(3):461-5. PubMed ID: 26252424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
    Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
    Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
    Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up.
    Roushan MR; Mohammadpour M; Baiany M; Soleimani S; Bijani A
    Epidemiol Infect; 2016 Sep; 144(12):2648-53. PubMed ID: 27268129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
    Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
    AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs.
    Liu Y; Zhang L; Zhou JY; Pan J; Hu W; Zhou YH
    PLoS One; 2016; 11(1):e0146980. PubMed ID: 26751075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
    Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
    PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.